These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26970248)

  • 21. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
    Li X; Strasser B; Jafari-Khouzani K; Thapa B; Small J; Cahill DP; Dietrich J; Batchelor TT; Andronesi OC
    Radiology; 2020 Mar; 294(3):589-597. PubMed ID: 31909698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
    Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status in Gliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics.
    Di Ieva A; Magnussen JS; McIntosh J; Mulcahy MJ; Pardey M; Choi C
    World Neurosurg; 2020 Jan; 133():e421-e427. PubMed ID: 31526886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.
    Branzoli F; Di Stefano AL; Capelle L; Ottolenghi C; Valabrègue R; Deelchand DK; Bielle F; Villa C; Baussart B; Lehéricy S; Sanson M; Marjanska M
    Neuro Oncol; 2018 Jun; 20(7):907-916. PubMed ID: 29126125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T.
    Crisi G; Filice S; Michiara M; Crafa P; Lana S
    J Comput Assist Tomogr; 2018; 42(3):469-474. PubMed ID: 29287025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
    Elkhaled A; Jalbert LE; Phillips JJ; Yoshihara HAI; Parvataneni R; Srinivasan R; Bourne G; Berger MS; Chang SM; Cha S; Nelson SJ
    Sci Transl Med; 2012 Jan; 4(116):116ra5. PubMed ID: 22238333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower Lactate Levels and Lower Intracellular pH in Patients with
    Wenger KJ; Steinbach JP; Bähr O; Pilatus U; Hattingen E
    AJNR Am J Neuroradiol; 2020 Aug; 41(8):1414-1422. PubMed ID: 32646946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study.
    Bertolino N; Marchionni C; Ghielmetti F; Burns B; Finocchiaro G; Anghileri E; Bruzzone MG; Minati L
    Phys Med; 2014 Sep; 30(6):702-7. PubMed ID: 24685182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo.
    An Z; Ganji SK; Tiwari V; Pinho MC; Patel T; Barnett S; Pan E; Mickey BE; Maher EA; Choi C
    Magn Reson Med; 2017 Jul; 78(1):40-48. PubMed ID: 27454352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
    Cuccarini V; Antelmi L; Pollo B; Paterra R; Calatozzolo C; Nigri A; DiMeco F; Eoli M; Finocchiaro G; Brenna G; Tramacere I; Bruzzone MG; Anghileri E
    Neurol Sci; 2020 Feb; 41(2):347-355. PubMed ID: 31650436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
    Molloy AR; Najac C; Viswanath P; Lakhani A; Subramani E; Batsios G; Radoul M; Gillespie AM; Pieper RO; Ronen SM
    Theranostics; 2020; 10(19):8757-8770. PubMed ID: 32754276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
    Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
    J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
    Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y
    Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
    Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
    Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.
    Tiwari V; Mashimo T; An Z; Vemireddy V; Piccirillo S; Askari P; Hulsey KM; Zhang S; de Graaf RA; Patel TR; Pan E; Mickey BE; Maher EA; Bachoo RM; Choi C
    Magn Reson Med; 2020 Sep; 84(3):1152-1160. PubMed ID: 32003035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of
    Di Stefano AL; Nichelli L; Berzero G; Valabregue R; Touat M; Capelle L; Pontoizeau C; Bielle F; Lerond J; Giry M; Villa C; Baussart B; Dehais C; Galanaud D; Baldini C; Savatovsky J; Dhermain F; Deelchand DK; Ottolenghi C; Lehéricy S; Marjańska M; Branzoli F; Sanson M
    Neurology; 2023 Jan; 100(1):e94-e106. PubMed ID: 36180241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exceptionally rare IDH1-mutant adult medulloblastoma with concurrent GNAS mutation revealed by in vivo magnetic resonance spectroscopy and deep sequencing.
    Liserre R; Branzoli F; Pagani F; Gryzik M; Cominelli M; Miele E; Marjańska M; Doglietto F; Poliani PL
    Acta Neuropathol Commun; 2023 Mar; 11(1):47. PubMed ID: 36941703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.